Эффективность и безопасность комбинированной терапии препаратами Алфузозин (Алфупрост® МР) и Солифенацин (Везигамп) у больных доброкачественной гиперплазией предстательной железы и гиперактивным мочевым пузырем: первые результаты наблюдательного многоцентрового исследования «Авиатор»

Эффективность и безопасность комбинированной терапии препаратами Алфузозин (Алфупрост® МР) и Солифенацин (Везигамп) у больных доброкачественной гиперплазией предстательной железы и гиперактивным мочевым пузырем: первые результаты наблюдательного многоцентрового исследования «Авиатор»

Автор: Сивков А.В., Ромих В.В., Пантелеев В.В., Кукушкина Л.Ю., Захарченко А.В., Шашин М.Н., Аль-шукри А.С., Нашивочникова Н.А., Заворина С.В., Ибишев Х.С., Крайний П.С., Шихотаров С.В., Шамарин А.А., Мотин А.В., Хилай Д.А.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Андрология

Статья в выпуске: 4 т.16, 2023 года.

Бесплатный доступ

Введение. Комбинированная терапия симптомов нарушения функции нижних мочевых путей, связанных с доброкачественной гиперплазией предстательной железы (СНМП/ДГПЖ), с применением а1-адреноблокаторов (а1-АБ) и антихолинергических препаратов (МХЛ) стала стандартом лечения и все шире применяется в клинической практике.

Доброкачественная гиперплазия предстательной железы, симптомы нарушения функции нижних мочевых путей, гиперактивность мочевого пузыря, комбинированное медикаментозное лечение, алфузозин, солифенацин

Короткий адрес: https://sciup.org/142240794

IDR: 142240794   |   DOI: 10.29188/2222-8543-2023-16-4-44-56

Список литературы Эффективность и безопасность комбинированной терапии препаратами Алфузозин (Алфупрост® МР) и Солифенацин (Везигамп) у больных доброкачественной гиперплазией предстательной железы и гиперактивным мочевым пузырем: первые результаты наблюдательного многоцентрового исследования «Авиатор»

  • Раснер П.И., Сивков А.В., Харчилава Р.Р. Клинические рекомендации. Доброкачественная гиперплазия предстательной железы. Одобрено Научно-практическим Советом Минздрава РФ 2020. 54 с. [Электронный ресурс]. [Rasner P.I., Sivkov A.V., Kharchilava R.R. Clinical guidelines Benign prostatic hyperplasia. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation 2020. 54 p. [Electronic resourse] (In Russian)]. URL: https://cr.minzdrav.gov.ru/schema/6_1.
  • Cornu JN, Gacci M, Hashim H, Herrmann RW, Malde S, Netsch C, et al. Nonneurogenic Male LUTS. EAU Guide-lines. EAU 2023, 106 p. [Electronic resourse]. URL: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/disease-management.
  • Wadie BS, el Ebrahim HE, Gomha MA. The relationship of detrusor instability and symptoms with objective parameters used for diagnosing bladder outlet obstruction: a prospective study. J Urol 2002;168(1):132–4.
  • Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Hofner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008; 54(2):419–26. https://doi.org/10.1016/j.eururo.2008.02.017.
  • Athanasopoulos A, Perimenis P. Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert Opin Pharmacother 2005;6(14):2429–33. https://doi.org/10.1517/14656566.6.14.2429.
  • Hofner K, Burkart M, Jacob G, Jonas U. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 2007;25(6):627–33. https://doi.org/10.1007/s00345-007-0212-5.
  • Abrams P, Kaplan S, Hendrik J, De Koning G, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;173(3 Pt 1):999–1004. https://doi.org/10.1016/S0022-5347(05)00483-0.
  • Lee HN, Lee KS, Kim JC, Chung BH, Kim CS, Lee JG, et al. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms. Int J Clin Pract 2015;69(4):444-53. https://doi.org/10.1111/ijcp.12581.
  • Mari A, Antonelli A, Cindolo L, Fusco F, Minervini A, De Nunzio C. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. Ther Adv Urol 2021;13:1756287221993283. https://doi.org/10.1177/1756287221993283.
  • Song K, Choo MS, Lee KS, Han JY, Lee YS, Kim JC, Cho JC. The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility. Urology 2011;77(5):1177–82. https://doi.org/10.1016/j.urology.2010.10.012.
  • Пушкарь Д.Ю., Лоран О.Б., Берников А.Н. Результаты реальной клинической практики влияния монотерапии алфузозином на сексуальную функцию пациентов с доброкачественной гиперплазией предстательной железы (итоги Российского многоцентрового исследования) Урология 2022;(6):21-9. [Pushkar D.Yu., Loran O.B., Bernikov A.N. The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study). Urologiya = Urologiia 2022;(6):21-9. (In Russian)].
  • Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol Urodyn 2009;28(1):52–7. https://doi.org/10.1002/nau.20586.
  • Kaplan SA, Goldfischer ER, Steers WD, Gittelman M, Andoh M, ForeroSchwanhaeuser S. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported out-comes. Aging Male 2010;13(2):100–7. https://doi.org/10.3109/13685530903440408.
  • Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64(6):1081-8. https://doi.org/10.1016/j.urology.2004.07.031.
  • Лопаткин Н.А., Сивков А.В., Суриков В.Н., Егоров А.А. Сравнительная оценка эффективности применения теразозина и тамсулозина у больных с доброкачественной гиперплазией предстательной железы. Урология 2002;(5 Приложение):3-12. [Lopatkin N.A., Sivkov A.V., Surikov V.N., Egorov A.A. Comparative assessment of the effectiveness of terazosin and tamsulosin in patients with benign prostatic hyperplasia. Urologiya = Urologiia 2002;(5 Suppl):3-12. (In Russian)].
  • Praus F, Miernik A. Silodosin zur Behandlung von Symptomen des unteren Harntraktes bei Männern mit gutartiger Prostatahyperplasie. Der Urologe 2019;58(7);795–8. [Praus F, Miernik A. LUTS in BPH patients: Comparison of silodosin versus tamsulosin, naftopidil, alfuzosin and placebo for the treatment of lower urinary tract symptoms. Der Urologe 2019;58(7);795–8.https://doi.org/10.1007/s00120-019-0955-9. (In German)].
  • Michel MC, Mehlburger L, Bressel HU, Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1998;1(6):332-5. https://doi.org/10.1038/sj.pcan.4500267.
  • Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract 2011;65(4):487–507. https://doi.org/10.1111/j.1742-1241.2010.02611.x
  • Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O, TAABO Study Group. Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Low Urin Tract Symptoms 2011;3(1):29-35. https://doi.org/10.1111/j.1757-5672.2010.00081.x.
  • Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169(6):2253-6. https://doi.org/10.1097/01.ju.0000067541.73285.eb.
  • Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004;94(6):817-20. https://doi.org/10.1111/j.1464-410X.2004.05039.x.
  • Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, et. al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, ran-domized, controlled multicenter study. J Urol 2005;174(4 Pt 1):1334-8. https://doi.org/10.1097/01.ju.0000173630.94559.fd.
  • Yang Y, Zhao X-f, Li H-z, Wang W, Zhang Y, Xiao H, Zhang X. Efficacy and safety of com-bined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 2007;120(5):370-4.
  • MacDiarmid SA, Peters KM, Chen A, Armstrong RB, Orman C, Aquilina JW, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008;83(9):1002-10. https://doi.org/10.4065/83.9.1002.
  • Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009;56(3):534-41. https://doi.org/10.1016/j.eururo.2008.11.026.
  • Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009;182(6):2825-30. https://doi.org/10.1016/j.juro.2009.08.023.
  • Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. BJU Int 2012;109(12):1831-40. https://doi.org/10.1111/j.1464-410X.2011.10624.x.
  • van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 2013;64(6):1003- 12. https://doi.org/10.1016/j.eururo.2013.07.034.
  • Gacci M, Sebastianelli A, Salvi M, Schiavina R, Brunocilla E, Novara G, et al. Tolterodine in the treatment of male LUTS. Curr Urol Rep 2015;16(9):60. https://doi.org/10.1007/s11934-015-0531-9.
  • Kim TH, Jung W, Suh YS, Yook S, Sung HH, Lee K. Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an alpha-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial. BJU Int 2016;117(2):307-15. https://doi.org/10.1111/bju.13267.
  • Athanasopoulos A, Chapple C, Fowler C, Gratzke C., Kaplan S., Stief C, et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011;60(1):94-105. https://doi.org/10.1016/j.eururo.2011.03.054.
  • Kim HJ, Sun HY, Choi H, Park JY, Bae JH, Doo S.W. et al. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated metaanalysis. PLoS One 2017;12(1):e0169248. https://doi.org/10.1371/journal.pone.0169248.
  • Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol 2013;64(23):398-407. https://doi.org/10.1016/j.eururo.2013.03.031.
  • Drake MJ, Chapple C, Sokol R, Oelke M, Traudtner K, Klaver M, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: Results from the NEPTUNE study and NEPTUNE II open-label extension. Eur Urol 2015;67(2):262-70. https://doi.org/10.1016/j.eururo.2014.07.013.
  • Drake MJ, Sokol R, Coyne K, Hakimi Z, Nazir J, Dorey J, et al. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin OCAS: results from the NEPTUNE study. BJU Int 2016;117(1):165-72. https://doi.org/10.1111/bju.13162.
  • Rees J, Foley S, Huang M, Arias JR, Skoumal R, Walters C, et al. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Neurourol Urodyn 2019;38(3):981-9. https://doi.org/10.1002/nau.23944
  • Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, Fakhoury A. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 2013;63(1):158-65. https://doi.org/10.1016/j.eururo.2012.07.003.
  • Lee SH, Byun SS, Lee SJ, Kim KH, Lee JY. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. Int Urol Nephrol 2014;46(3):523-9. https://doi.org/10.1007/s11255-013-0551-7.
  • Cho HJ, Shin SC, Seo DY, Cho JM, Kang JY, Yoo TK, et al. Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an over-active bladder: randomised, single-blind, prospective study. Int J Clin Pract 2014;68(4):471-7. https://doi.org/10.1111/ijcp.12339.
  • Kaplan SA, Roehrborn CG, Rovner EC, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296(19):2319-28. DOI: 10.1001/jama.296.19.2319. M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296(19):2319-28. https://doi.org/10.1001/jama.296.19.2319.
  • Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2007;99(1):85-96. https://doi.org/10.1111/j.1464-410X.2006.06574.x.
  • Gong M, Dong W, Huang H, Gong Z, Deng D, Qiu S, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin 2015;31(9):1781-92. https://doi.org/10.1185/03007995.2015.1074067.
  • Drake MJ, Oelke M, Snijder R, Klaver M, Traudtner K, van Charldorp K. et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEP-TUNE/NEPTUNE II randomized controlled studies. PLoS One 2017;12(2):e0170726. https://doi.org/10.1371/journal.pone.0170726.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp